A Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi’s sarcoma (KS).

Trial Overview and Summary

Chief Investigator: Dr Robin Young
Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Funders: CRUK & AstraZeneca
Disease Site: AIDS-assosiated Kaposi's Sarcoma (KS)
Trial Type: Clinical Trial of an Investigational Medical Product
Status: Closed
UKCRN Study ID: (if applicable) 11876
Open to new sites? No
Recruitment start date: June 2012
Anticipated Recruitment end date December 2016
CRCTU Trial Management Team: Early Drug Development Team
Trial E-mail Address:

Trial Summary

  • View Trial Summary Document [.pdf]

Cancer is a leading cause of death in individuals living with HIV, and Kaposi's sarcoma (KS) remains the commonest HIV-associated cancer. KS results from co-infection with HIV and another virus, HHV-8. Laboratory studies have shown that HHV-8 viral proteins stimulate intracellular signalling pathways within KS lesions which promotes their growth. Selumetinib targets these signalling pathways and may therefore be a useful new therapy for KS.

SCART is a national multi-centre study. The objectives of the SCART trial are to determine a safe and tolerable dose for selumetinib in combination with HIV anti-retroviral therapy, and to determine whether selumetinib reduces KS lesions in HIV positive patients.

Trial Protocol

Please Note:
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website see the link below.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

  • View Trial Protocol Document

More information